New Assay That Mimics How SARS-CoV-2 Infects Cells Could Speed Up Discovery of COVID-19 Treatments
|
By HospiMedica International staff writers Posted on 23 Sep 2020 |

Image: Scientists have developed a new tool that mimics how SARS-CoV-2 infects a cell, information that could potentially speed the search for treatments against the disease (Photo courtesy of NIH)
Scientists have developed a new tool that mimics how SARS-CoV-2 infects a cell, information that could potentially speed the search for treatments against the disease.
The tool developed by a team of scientists from the NIH’s National Center for Advancing Translational Sciences (NCATS Bethesda, MA, USA) and Naval Research Laboratory (NRL Washington, DC, USA) is a fluorescent nanoparticle probe that uses the spike protein on the surface of SARS-CoV-2 to bind to cells and trigger the process that pulls the virus into the cell. The probe could be used in tests to rapidly gauge the ability of biologics, drugs and compounds to block the actual virus from infecting human cells.
Since using the actual virus in such screening studies would be difficult and require special facilities, the team wanted to use nanoparticles to mimic the viral function of binding to and invading the host human cell. To create the probe, NRL scientists built a fluorescent nanoparticle called a quantum dot, fashioned from cadmium and selenium. At around 10 nanometers in size, these spherical nanoparticles are 3,000 times smaller than the width of a human hair. The research team then studded the quantum dots’ surfaces with a section of the SARS-CoV-2 spike protein that binds to the angiotensin-converting enzyme 2 (ACE2) receptor on human cells. The union of the spike protein with ACE2 is the first step in the pathway to viral infection. The glow from the quantum dots allows scientists to track the dots’ behavior under a microscope.
The investigators tracked how the quantum dot probes interacted with human cells that have ACE2 on their surfaces. They watched the nanoparticle probes attach to ACE2, which combined with the probes and pulled them into the cells. The quantum dot probes did the same in a lung cell line commonly used in coronavirus assays. Safety data showed that the probes were not toxic to the test cells at the concentrations and exposure times used in the study. The quantum dots followed the SARS-CoV-2 pathway into cells, but the research team found the probes also mimicked the virus in the presence of antibodies. Antibodies are proteins made by the immune system that can neutralize viruses such as SARS-CoV-2. The antibodies proved to be potent inhibitors of the quantum dot probes as well, preventing them from binding to ACE2 and entering human cells. That antibody response means the quantum dot probes could help researchers rapidly test the ability of potential therapeutic agents to block the virus from entering and infecting cells. Assays using the probes also could determine the concentrations at which potential treatments may safely and effectively block infection.
ACE2 may not be the only receptor SARS-CoV-2 targets, and the quantum dot probe’s flexible design will allow researchers to swap in spikes that bind to other receptors. With the probe, researchers also could test how mutations in the spike change the way the virus behaves - and how well treatments work - by adding the mutated spikes to the quantum dots. Beyond SARS-CoV-2, researchers could revise the nanoparticle probe to mimic other viruses and reveal their pathways to infection. The quantum dot probes also could be useful when testing potential therapies for other diseases, according to the researchers. The quantum dots also might deliver drugs directly to cells, narrowing treatment to specific cell types, organs or cancers.
“Our goal is to create a screening system to find compounds that block SARS-CoV-2 from binding to cells and infecting them,” said Kirill Gorshkov, Ph.D., a translational scientist at NCATS and a co-corresponding author of the study. “Using the quantum dots, we could create tests to use in drug screening and drug repurposing, using libraries of compounds that have activity but that also are approved by the US Food and Drug Administration. Such assays could rapidly identify promising, safe treatments for COVID-19.”
Related Links:
National Center for Advancing Translational Sciences
Naval Research Laboratory
The tool developed by a team of scientists from the NIH’s National Center for Advancing Translational Sciences (NCATS Bethesda, MA, USA) and Naval Research Laboratory (NRL Washington, DC, USA) is a fluorescent nanoparticle probe that uses the spike protein on the surface of SARS-CoV-2 to bind to cells and trigger the process that pulls the virus into the cell. The probe could be used in tests to rapidly gauge the ability of biologics, drugs and compounds to block the actual virus from infecting human cells.
Since using the actual virus in such screening studies would be difficult and require special facilities, the team wanted to use nanoparticles to mimic the viral function of binding to and invading the host human cell. To create the probe, NRL scientists built a fluorescent nanoparticle called a quantum dot, fashioned from cadmium and selenium. At around 10 nanometers in size, these spherical nanoparticles are 3,000 times smaller than the width of a human hair. The research team then studded the quantum dots’ surfaces with a section of the SARS-CoV-2 spike protein that binds to the angiotensin-converting enzyme 2 (ACE2) receptor on human cells. The union of the spike protein with ACE2 is the first step in the pathway to viral infection. The glow from the quantum dots allows scientists to track the dots’ behavior under a microscope.
The investigators tracked how the quantum dot probes interacted with human cells that have ACE2 on their surfaces. They watched the nanoparticle probes attach to ACE2, which combined with the probes and pulled them into the cells. The quantum dot probes did the same in a lung cell line commonly used in coronavirus assays. Safety data showed that the probes were not toxic to the test cells at the concentrations and exposure times used in the study. The quantum dots followed the SARS-CoV-2 pathway into cells, but the research team found the probes also mimicked the virus in the presence of antibodies. Antibodies are proteins made by the immune system that can neutralize viruses such as SARS-CoV-2. The antibodies proved to be potent inhibitors of the quantum dot probes as well, preventing them from binding to ACE2 and entering human cells. That antibody response means the quantum dot probes could help researchers rapidly test the ability of potential therapeutic agents to block the virus from entering and infecting cells. Assays using the probes also could determine the concentrations at which potential treatments may safely and effectively block infection.
ACE2 may not be the only receptor SARS-CoV-2 targets, and the quantum dot probe’s flexible design will allow researchers to swap in spikes that bind to other receptors. With the probe, researchers also could test how mutations in the spike change the way the virus behaves - and how well treatments work - by adding the mutated spikes to the quantum dots. Beyond SARS-CoV-2, researchers could revise the nanoparticle probe to mimic other viruses and reveal their pathways to infection. The quantum dot probes also could be useful when testing potential therapies for other diseases, according to the researchers. The quantum dots also might deliver drugs directly to cells, narrowing treatment to specific cell types, organs or cancers.
“Our goal is to create a screening system to find compounds that block SARS-CoV-2 from binding to cells and infecting them,” said Kirill Gorshkov, Ph.D., a translational scientist at NCATS and a co-corresponding author of the study. “Using the quantum dots, we could create tests to use in drug screening and drug repurposing, using libraries of compounds that have activity but that also are approved by the US Food and Drug Administration. Such assays could rapidly identify promising, safe treatments for COVID-19.”
Related Links:
National Center for Advancing Translational Sciences
Naval Research Laboratory
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Critical Care
view channel
CPR Guidelines Updated for Pediatric and Neonatal Emergency Care and Resuscitation
Cardiac arrest in infants and children remains a leading cause of pediatric emergencies, with more than 7,000 out-of-hospital and 20,000 in-hospital cardiac arrests occurring annually in the United States.... Read more
Ingestible Capsule Monitors Intestinal Inflammation
Acute mesenteric ischemia—a life-threatening condition caused by blocked blood flow to the intestines—remains difficult to diagnose early because its symptoms often mimic common digestive problems.... Read more
Wireless Implantable Sensor Enables Continuous Endoleak Monitoring
Endovascular aneurysm repair (EVAR) is a life-saving, minimally invasive treatment for abdominal aortic aneurysms—balloon-like bulges in the aorta that can rupture with fatal consequences.... Read more
Wearable Patch for Early Skin Cancer Detection to Reduce Unnecessary Biopsies
Skin cancer remains one of the most dangerous and common cancers worldwide, with early detection crucial for improving survival rates. Traditional diagnostic methods—visual inspections, imaging, and biopsies—can... Read moreSurgical Techniques
view channel
Robotic Assistant Delivers Ultra-Precision Injections with Rapid Setup Times
Age-related macular degeneration (AMD) is a leading cause of blindness worldwide, affecting nearly 200 million people, a figure expected to rise to 280 million by 2040. Current treatment involves doctors... Read more
Minimally Invasive Endoscopic Surgery Improves Severe Stroke Outcomes
Intracerebral hemorrhage, a type of stroke caused by bleeding deep within the brain, remains one of the most challenging neurological emergencies to treat. Accounting for about 15% of all strokes, it carries... Read morePatient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read moreFirst-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel
Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies
Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
B. Braun Acquires Digital Microsurgery Company True Digital Surgery
The high-end microsurgery market in neurosurgery, spine, and ENT is undergoing a significant transformation. Traditional analog microscopes are giving way to digital exoscopes, which provide improved visualization,... Read more
CMEF 2025 to Promote Holistic and High-Quality Development of Medical and Health Industry
The 92nd China International Medical Equipment Fair (CMEF 2025) Autumn Exhibition is scheduled to be held from September 26 to 29 at the China Import and Export Fair Complex (Canton Fair Complex) in Guangzhou.... Read more








